search

Active clinical trials for "Kidney Failure, Chronic"

Results 431-440 of 1823

Vascular Reactivity in Kidney Disease Patients

Kidney FailureChronic4 more

Dialysis patients suffer from many problems with blood vessels and this is even more so for patients with the added complication of diabetes. Diabetics have a number of reasons for vascular disease and one of the new areas of research is looking at the cells that line the blood vessels, called endothelial cells. It is thought that the number of red blood cells in the blood (haemoglobin concentration) affects the function of these cells. There is very little information available on what haemoglobin level is best for dialysis patients. As diabetics account for almost 40% of dialysis patients worldwide it is important to understand the effect different haemoglobin levels will have on the blood vessels. Hypothesis: Endothelial cell function and the related expansile capacity of blood vessels are affected by different haemoglobin concentrations [Hb] in dialysis patients.

Completed19 enrollment criteria

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving...

AnemiaIron-Deficiency2 more

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents, such as Procrit® and Aranesp®.

Completed7 enrollment criteria

Efficacy and Safety Study of GerEPO

Chronic Renal Failure Related Anemia

The purpose of the study is to establish the equivalence of GerEpo with the standard treatment Eprex® for a treatment period of 12 weeks in patients on Hemodialysis with respect to hemoglobin response and to establish the longer-term safety profile of GerEpo, with special regards for the occurrence of Pure Red Cell Aplasia (PRCA) and other immunogenicity related adverse event

Completed16 enrollment criteria

Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease

Chronic Hepatitis CEnd Stage Renal Disease

The treatment response with conventional interferon alpha alone in patients with end stage renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is 17-29.6%. Pegylated interferon alpha, a newly developed form of interferon with superior pharmacokinetic profiles, has not been used to treatment these patients. We expect the better treatment response treated with peginterferon alpha than conventional interferon. In addition, we also observe the safety of the two drugs during the study. The goal of the study is to compare the efficacy and safety of the two different treatment regimens in patients with chronic hepatitis C and end stage renal disease.

Completed16 enrollment criteria

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

End-stage Renal DiseaseRenal Transplantation1 more

This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a relative with the same (or nearly the same) blood cell type as the transplant recipient. An investigational medication will be given prior to and after the transplant to help protect the transplanted kidney from attack by the body's immune system.

Completed17 enrollment criteria

Effects of Daily Home Hemodialysis on Circulation, Mental Functions, and Quality of Life

End-Stage Renal Disease

This study was designed to discover mechanisms responsible for the decrease in (high) blood pressure after starting daily hemodialysis, as has been observed by various investigators. We hypothesized that better control of body water and sodium content and a decline in the autonomic (sympathetic) nervous system activity, increased in chronic renal failure patients, would contribute to improved blood pressure regulation. Moreover, we studied the effects of daily hemodialysis on mental functions, like information processing and memory, in relation to the previously reported improvement in quality of life, and the effects on nutrition. We hypothesized that all would improve.

Completed5 enrollment criteria

Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis...

Kidney FailureChronic

The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride

Completed6 enrollment criteria

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and...

Diabetic Nephropathy

The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.

Terminated33 enrollment criteria

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

End Stage Renal Disease

The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product.

Completed1 enrollment criteria

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

AnemiaChronic Kidney Disease2 more

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

Completed4 enrollment criteria
1...434445...183

Need Help? Contact our team!


We'll reach out to this number within 24 hrs